10-Q: Intelligent Bio Solutions Reports Q3 2024 Results, Revenue Growth Offset by Operating Losses

Intelligent Bio Solutions Inc. reports increased revenue for Q3 2024, driven by its Intelligent Fingerprinting Products, but continues to experience operating losses and identifies material weaknesses in internal controls.

Summary

• Intelligent Bio Solutions Inc. reported a net loss of $2.98 million for the three months ended March 31, 2024, and a net loss of $7.39 million for the nine months ended March 31, 2024.
• The company's revenue for the quarter was $823,800, and $2.38 million for the nine months, primarily from sales of its Intelligent Fingerprinting Products.
• Operating expenses totaled $3.21 million for the quarter and $8.42 million for the nine months, including significant selling, general, and administrative costs.
• The company's cash and cash equivalents stood at $9.39 million as of March 31, 2024, with a working capital of $5.81 million.
• The company has identified material weaknesses in its internal control over financial reporting and is taking steps to remediate these issues.
• The company has raised approximately $10.76 million through a warrant inducement transaction and a private placement offering of the company's securities.
• The company has secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is revenue growth and successful capital raising, the significant operating losses, material weaknesses in internal controls, and going concern risk raise concerns. The sentiment is therefore cautiously negative.

Positives

• The company experienced significant revenue growth in the quarter and nine months ended March 31, 2024.
• The company has successfully raised additional capital through various financing activities.
• The company is expanding its customer base and securing new partnerships.
• The company is progressing with its FDA 510(k) clinical studies plan.
• The company has secured a new European patent for its DSR-Plus Cartridge Reader.

Negatives

• The company reported a net loss of $2.98 million for the quarter and $7.39 million for the nine months ended March 31, 2024.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company anticipates operating losses for the foreseeable future.
• The company's cash and cash equivalents may be insufficient to fund its current operating plan for the next twelve months.
• The company's operating expenses remain high.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company's internal control over financial reporting has material weaknesses.
• The company may not be able to satisfy the continued listing requirements of the Nasdaq Capital Market.
• The company's intellectual property rights may be affected by the liquidation of its licensor, LSBD.
• The company may be liable to refund the government grant if it fails to achieve certain milestones.

Future Outlook

The company anticipates operating losses for the foreseeable future and may need to raise additional funds to meet its working capital needs. The company expects to continue expanding its customer base and progressing with its FDA 510(k) clinical studies plan.

Management Comments

• Management is committed to continuing the steps necessary to remediate the control deficiencies that constituted the material weaknesses.
• Management believes that the company's cash and cash equivalents as of March 31, 2024, may be insufficient to allow the company to fund its current operating plan through at least the next twelve months.

Industry Context

The company operates in the medical technology sector, focusing on non-invasive testing and screening solutions. The company's Intelligent Fingerprinting Products compete with traditional drug testing methods, while its Saliva Glucose Biosensor aims to provide an alternative to invasive blood glucose monitoring. The company's financial results and operational updates are relevant to investors and stakeholders in the medical device and diagnostics industry.

Comparison to Industry Standards

• The company's revenue growth is a positive sign, but its continued operating losses are a concern compared to established medical device companies.
• The identification of material weaknesses in internal controls is a significant issue that needs to be addressed to meet industry standards for financial reporting.
• The company's cash position is relatively low compared to other companies in the sector, raising concerns about its ability to fund operations and growth.
• The company's reliance on external funding is a common trait for early-stage medical technology companies, but the company needs to demonstrate a clear path to profitability.
• The company's progress with its FDA 510(k) clinical studies plan is a positive development, but the regulatory approval process can be lengthy and costly.

Related Party Transactions

• Spiro Sakiris, the company's Chief Financial Officer, purchased 112,727 units in the October 2023 Offering.
• Christopher Towers, a member of the company's Board of Directors, purchased 9,090 units in the October 2023 Offering.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential stock price volatility.
• Employees may be affected by potential cost-cutting measures if the company's financial situation does not improve.
• Customers may be impacted by potential delays in product development or commercialization.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
• The company's ability to continue as a going concern is dependent on raising additional capital.

Next Steps

• The company will continue to take measures to remediate the material weaknesses in its internal control over financial reporting.
• The company plans to discuss the future licensing of SGT products with the University of Newcastle.
• The company will continue to progress with its FDA 510(k) clinical studies plan.
• The company will continue to expand its customer base and secure new partnerships.

Key Dates

Keywords

Intelligent Bio Solutions, INBS, Intelligent Fingerprinting Products, Saliva Glucose Biosensor, FDA 510(k), Financial Results, Reverse Stock Split, Warrant Inducement, Private Placement, Material Weakness, Going Concern, Clinical Study, European Patent